Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

What happened

Eli Lilly and Hims & Hers announced an agreement to offer eligible patients prescribed Zepbound or Foundayo through Hims & Hers’ platform the same self-pay prices available to other patients. The platform will handle consultation and prescription steps and arrange home delivery; monthly prices start at $149 for Foundayo and $299 for Zepbound.

Confirmed

Global impact / market context

The agreement adds Hims & Hers as a direct route for eligible patients to obtain Lilly’s obesity medicines, combining online consultations with Lilly products and home delivery. If more patients use this route, it could support medicine sales while giving Hims & Hers a broader service offering.

Analyst inference

The announcement connects a consumer health platform with Lilly’s FDA-approved obesity medicines, with patients paying directly rather than relying on a stated insurance arrangement. The article provides no sales forecasts, expected patient numbers, financial terms, or evidence of a market reaction.

Confirmed

What to watch

1. Whether eligible patients complete consultations and receive prescriptions will determine how many can use the new route; providers retain discretion over whether treatment is appropriate. Confirmed
2. Any later disclosure of patient uptake, sales contribution, or financial terms could clarify whether this agreement meaningfully adds revenue for Lilly or Hims & Hers. Analyst inference
3. Watch whether the announced starting prices and platform-based access remain available as described; the article does not state how pricing or eligibility may change over time. Analyst inference

Evidence

• Original source link unavailable